Halozyme Therapeutics, Inc. (HALO) — 8-K Filings

8-K Filings (16)

• Halozyme Therapeutics Announces Executive and Board Changes — Dec 9, 2025 Risk: medium
  On December 4, 2025, Halozyme Therapeutics, Inc. announced changes in its executive team and board of directors. The filing details the departure of certain off
• Halozyme Therapeutics Reports Executive Compensation Changes — Dec 8, 2025 Risk: low
  On December 4, 2025, Halozyme Therapeutics, Inc. reported changes in its executive and director compensation arrangements. The filing details adjustments to the
• 8-K Filing — Nov 24, 2025
• Halozyme Therapeutics Files 8-K with Key Agreements and Securities Info — Nov 12, 2025 Risk: medium
  On November 6, 2025, Halozyme Therapeutics, Inc. entered into a material definitive agreement. The company also reported the creation of a direct financial obli
• Halozyme Therapeutics Files 8-K — Nov 7, 2025 Risk: low
  On November 6, 2025, Halozyme Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with
• 8-K Filing — Nov 5, 2025
• Halozyme Therapeutics Files 8-K — Oct 14, 2025 Risk: low
  On October 14, 2025, Halozyme Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhib
• Halozyme Therapeutics Announces Executive & Director Changes — Oct 6, 2025 Risk: medium
  On October 1, 2025, Halozyme Therapeutics, Inc. filed an 8-K report detailing changes in its executive and director compensation arrangements. The filing also a
• Halozyme Therapeutics Files 8-K for Material Agreement — Oct 3, 2025 Risk: medium
  On September 30, 2025, Halozyme Therapeutics, Inc. entered into a material definitive agreement. The company, headquartered in San Diego, California, filed an 8
• Halozyme Therapeutics Files 8-K — Oct 1, 2025 Risk: low
  On September 30, 2025, Halozyme Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibit
• Halozyme Therapeutics Files 8-K on Security Holder Vote — May 2, 2025 Risk: low
  On May 1, 2025, Halozyme Therapeutics, Inc. filed an 8-K report indicating that matters were submitted to a vote of security holders. The filing does not disclo
• Halozyme Therapeutics Reports Director and Officer Changes — Mar 21, 2025 Risk: medium
  On March 17, 2025, Halozyme Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The fili
• Halozyme Therapeutics Announces Executive and Board Changes — Feb 13, 2025 Risk: medium
  On February 11, 2025, Halozyme Therapeutics, Inc. announced changes in its executive team, including the departure of certain officers and the election of new d
• Halozyme Therapeutics Files 8-K on Financials — Jan 8, 2025 Risk: low
  On January 8, 2025, Halozyme Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition,
• Halozyme Therapeutics Files 8-K on Shareholder Vote and Exhibits — Apr 26, 2024 Risk: low
  On April 25, 2024, Halozyme Therapeutics, Inc. filed an 8-K to report on the submission of matters to a vote of security holders and financial statements and ex
• HALOZYME Files 8-K on Operations & Financial Condition — Jan 17, 2024
  HALOZYME THERAPEUTICS, INC. filed an 8-K on January 17, 2024, to report on its Results of Operations and Financial Condition. This filing, under Commission File

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX